Research ExplorerPublicationsPermanent Pacemaker Implantation Following Valve-in-Valve Tr...

Permanent Pacemaker Implantation Following Valve-in-Valve Transcatheter Aortic Valve Replacement: VIVID Registry

Standard

Permanent Pacemaker Implantation Following Valve-in-Valve Transcatheter Aortic Valve Replacement: VIVID Registry. / Alperi, Alberto; Rodés-Cabau, Josep; Simonato, Matheus; Tchetche, Didier; Charbonnier, Gaetan; Ribeiro, Henrique B; Latib, Azeem; Montorfano, Matteo; Barbanti, Marco; Bleiziffer, Sabine; Redfors, Björn; Abdel-Wahab, Mohamed; Allali, Abdelhakim; Bruschi, Giuseppe; Napodano, Massimo; Agrifoglio, Marco; Petronio, Anna Sonia; Giannini, Cristina; Chan, Albert; Kornowski, Ran; Pravda, Nili Schamroth; Adam, Matti; Iadanza, Alessandro; Noble, Stephane; Chatfield, Andrew; Erlebach, Magdalena; Kempfert, Jörg; Ubben, Timm; Wijeysundera, Harindra; Seiffert, Moritz; Pilgrim, Thomas; Kim, Won-Keun; Testa, Luca; Hildick-Smith, David; Nerla, Roberto; Fiorina, Claudia; Brinkmann, Christina; Conzelmann, Lars; Champagnac, Didier; Saia, Francesco; Nissen, Henrik; Amrane, Hafid; Whisenant, Brian; Shamekhi, Jasmin; Søndergaard, Lars; Webb, John G; Dvir, Danny.

In: J AM COLL CARDIOL, Vol. 77, No. 18, 11.05.2021, p. 2263-2273.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Alperi, A, Rodés-Cabau, J, Simonato, M, Tchetche, D, Charbonnier, G, Ribeiro, HB, Latib, A, Montorfano, M, Barbanti, M, Bleiziffer, S, Redfors, B, Abdel-Wahab, M, Allali, A, Bruschi, G, Napodano, M, Agrifoglio, M, Petronio, AS, Giannini, C, Chan, A, Kornowski, R, Pravda, NS, Adam, M, Iadanza, A, Noble, S, Chatfield, A, Erlebach, M, Kempfert, J, Ubben, T, Wijeysundera, H, Seiffert, M, Pilgrim, T, Kim, W-K, Testa, L, Hildick-Smith, D, Nerla, R, Fiorina, C, Brinkmann, C, Conzelmann, L, Champagnac, D, Saia, F, Nissen, H, Amrane, H, Whisenant, B, Shamekhi, J, Søndergaard, L, Webb, JG & Dvir, D 2021, 'Permanent Pacemaker Implantation Following Valve-in-Valve Transcatheter Aortic Valve Replacement: VIVID Registry', J AM COLL CARDIOL, vol. 77, no. 18, pp. 2263-2273. https://doi.org/10.1016/j.jacc.2021.03.228

APA

Alperi, A., Rodés-Cabau, J., Simonato, M., Tchetche, D., Charbonnier, G., Ribeiro, H. B., Latib, A., Montorfano, M., Barbanti, M., Bleiziffer, S., Redfors, B., Abdel-Wahab, M., Allali, A., Bruschi, G., Napodano, M., Agrifoglio, M., Petronio, A. S., Giannini, C., Chan, A., ... Dvir, D. (2021). Permanent Pacemaker Implantation Following Valve-in-Valve Transcatheter Aortic Valve Replacement: VIVID Registry. J AM COLL CARDIOL, 77(18), 2263-2273. https://doi.org/10.1016/j.jacc.2021.03.228

Vancouver

Alperi A, Rodés-Cabau J, Simonato M, Tchetche D, Charbonnier G, Ribeiro HB et al. Permanent Pacemaker Implantation Following Valve-in-Valve Transcatheter Aortic Valve Replacement: VIVID Registry. J AM COLL CARDIOL. 2021 May 11;77(18):2263-2273. https://doi.org/10.1016/j.jacc.2021.03.228

Bibtex

@article{ec97a14aca224063838295a08b4fccbc,
title = "Permanent Pacemaker Implantation Following Valve-in-Valve Transcatheter Aortic Valve Replacement: VIVID Registry",
abstract = "BACKGROUND: Permanent pacemaker implantation (PPI) remains one of the main drawbacks of transcatheter aortic valve replacement (TAVR), but scarce data exist on PPI after valve-in-valve (ViV) TAVR, particularly with the use of newer-generation transcatheter heart valves (THVs).OBJECTIVES: The goal of this study was to determine the incidence, factors associated with, and clinical impact of PPI in a large series of ViV-TAVR procedures.METHODS: Data were obtained from the multicenter VIVID Registry and included the main baseline and procedural characteristics, in-hospital and late (median follow-up: 13 months [interquartile range: 3 to 41 months]) outcomes analyzed according to the need of periprocedural PPI. All THVs except CoreValve, Cribier-Edwards, Sapien, and Sapien XT were considered to be new-generation THVs.RESULTS: A total of 1,987 patients without prior PPI undergoing ViV-TAVR from 2007 to 2020 were included. Of these, 128 patients (6.4%) had PPI after TAVR, with a significant decrease in the incidence of PPI with the use of new-generation THVs (4.7% vs. 7.4%; p = 0.017), mainly related to a reduced PPI rate with the Evolut R/Pro versus CoreValve (3.7% vs. 9.0%; p = 0.002). There were no significant differences in PPI rates between newer-generation balloon- and self-expanding THVs (6.1% vs. 3.9%; p = 0.18). In the multivariable analysis, older age (odds ratio [OR]: 1.05 for each increase of 1 year; 95% confidence interval [CI]: 1.02 to 1.07; p = 0.001), larger THV size (OR: 1.10; 95% CI: 1.01 to 1.20; p = 0.02), and previous right bundle branch block (OR: 2.04; 95% CI: 1.00 to 4.17; p = 0.05) were associated with an increased risk of PPI. There were no differences in 30-day mortality between the PPI (4.7%) and no-PPI (2.7%) groups (p = 0.19), but PPI patients exhibited a trend toward higher mortality risk at follow-up (hazard ratio: 1.39; 95% CI: 1.02 to 1.91; p = 0.04; p = 0.08 after adjusting for age differences between groups).CONCLUSIONS: In a contemporary large series of ViV-TAVR patients, the rate of periprocedural PPI was relatively low, and its incidence decreased with the use of new-generation THV systems. PPI following ViV-TAVR was associated with a trend toward increased mortality at follow-up.",
keywords = "Aged, Aged, 80 and over, Female, Humans, Male, Pacemaker, Artificial, Prosthesis Implantation, Registries, Transcatheter Aortic Valve Replacement/methods",
author = "Alberto Alperi and Josep Rod{\'e}s-Cabau and Matheus Simonato and Didier Tchetche and Gaetan Charbonnier and Ribeiro, {Henrique B} and Azeem Latib and Matteo Montorfano and Marco Barbanti and Sabine Bleiziffer and Bj{\"o}rn Redfors and Mohamed Abdel-Wahab and Abdelhakim Allali and Giuseppe Bruschi and Massimo Napodano and Marco Agrifoglio and Petronio, {Anna Sonia} and Cristina Giannini and Albert Chan and Ran Kornowski and Pravda, {Nili Schamroth} and Matti Adam and Alessandro Iadanza and Stephane Noble and Andrew Chatfield and Magdalena Erlebach and J{\"o}rg Kempfert and Timm Ubben and Harindra Wijeysundera and Moritz Seiffert and Thomas Pilgrim and Won-Keun Kim and Luca Testa and David Hildick-Smith and Roberto Nerla and Claudia Fiorina and Christina Brinkmann and Lars Conzelmann and Didier Champagnac and Francesco Saia and Henrik Nissen and Hafid Amrane and Brian Whisenant and Jasmin Shamekhi and Lars S{\o}ndergaard and Webb, {John G} and Danny Dvir",
note = "Copyright {\textcopyright} 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.",
year = "2021",
month = may,
day = "11",
doi = "10.1016/j.jacc.2021.03.228",
language = "English",
volume = "77",
pages = "2263--2273",
journal = "J AM COLL CARDIOL",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "18",

}

RIS

TY - JOUR

T1 - Permanent Pacemaker Implantation Following Valve-in-Valve Transcatheter Aortic Valve Replacement: VIVID Registry

AU - Alperi, Alberto

AU - Rodés-Cabau, Josep

AU - Simonato, Matheus

AU - Tchetche, Didier

AU - Charbonnier, Gaetan

AU - Ribeiro, Henrique B

AU - Latib, Azeem

AU - Montorfano, Matteo

AU - Barbanti, Marco

AU - Bleiziffer, Sabine

AU - Redfors, Björn

AU - Abdel-Wahab, Mohamed

AU - Allali, Abdelhakim

AU - Bruschi, Giuseppe

AU - Napodano, Massimo

AU - Agrifoglio, Marco

AU - Petronio, Anna Sonia

AU - Giannini, Cristina

AU - Chan, Albert

AU - Kornowski, Ran

AU - Pravda, Nili Schamroth

AU - Adam, Matti

AU - Iadanza, Alessandro

AU - Noble, Stephane

AU - Chatfield, Andrew

AU - Erlebach, Magdalena

AU - Kempfert, Jörg

AU - Ubben, Timm

AU - Wijeysundera, Harindra

AU - Seiffert, Moritz

AU - Pilgrim, Thomas

AU - Kim, Won-Keun

AU - Testa, Luca

AU - Hildick-Smith, David

AU - Nerla, Roberto

AU - Fiorina, Claudia

AU - Brinkmann, Christina

AU - Conzelmann, Lars

AU - Champagnac, Didier

AU - Saia, Francesco

AU - Nissen, Henrik

AU - Amrane, Hafid

AU - Whisenant, Brian

AU - Shamekhi, Jasmin

AU - Søndergaard, Lars

AU - Webb, John G

AU - Dvir, Danny

N1 - Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

PY - 2021/5/11

Y1 - 2021/5/11

N2 - BACKGROUND: Permanent pacemaker implantation (PPI) remains one of the main drawbacks of transcatheter aortic valve replacement (TAVR), but scarce data exist on PPI after valve-in-valve (ViV) TAVR, particularly with the use of newer-generation transcatheter heart valves (THVs).OBJECTIVES: The goal of this study was to determine the incidence, factors associated with, and clinical impact of PPI in a large series of ViV-TAVR procedures.METHODS: Data were obtained from the multicenter VIVID Registry and included the main baseline and procedural characteristics, in-hospital and late (median follow-up: 13 months [interquartile range: 3 to 41 months]) outcomes analyzed according to the need of periprocedural PPI. All THVs except CoreValve, Cribier-Edwards, Sapien, and Sapien XT were considered to be new-generation THVs.RESULTS: A total of 1,987 patients without prior PPI undergoing ViV-TAVR from 2007 to 2020 were included. Of these, 128 patients (6.4%) had PPI after TAVR, with a significant decrease in the incidence of PPI with the use of new-generation THVs (4.7% vs. 7.4%; p = 0.017), mainly related to a reduced PPI rate with the Evolut R/Pro versus CoreValve (3.7% vs. 9.0%; p = 0.002). There were no significant differences in PPI rates between newer-generation balloon- and self-expanding THVs (6.1% vs. 3.9%; p = 0.18). In the multivariable analysis, older age (odds ratio [OR]: 1.05 for each increase of 1 year; 95% confidence interval [CI]: 1.02 to 1.07; p = 0.001), larger THV size (OR: 1.10; 95% CI: 1.01 to 1.20; p = 0.02), and previous right bundle branch block (OR: 2.04; 95% CI: 1.00 to 4.17; p = 0.05) were associated with an increased risk of PPI. There were no differences in 30-day mortality between the PPI (4.7%) and no-PPI (2.7%) groups (p = 0.19), but PPI patients exhibited a trend toward higher mortality risk at follow-up (hazard ratio: 1.39; 95% CI: 1.02 to 1.91; p = 0.04; p = 0.08 after adjusting for age differences between groups).CONCLUSIONS: In a contemporary large series of ViV-TAVR patients, the rate of periprocedural PPI was relatively low, and its incidence decreased with the use of new-generation THV systems. PPI following ViV-TAVR was associated with a trend toward increased mortality at follow-up.

AB - BACKGROUND: Permanent pacemaker implantation (PPI) remains one of the main drawbacks of transcatheter aortic valve replacement (TAVR), but scarce data exist on PPI after valve-in-valve (ViV) TAVR, particularly with the use of newer-generation transcatheter heart valves (THVs).OBJECTIVES: The goal of this study was to determine the incidence, factors associated with, and clinical impact of PPI in a large series of ViV-TAVR procedures.METHODS: Data were obtained from the multicenter VIVID Registry and included the main baseline and procedural characteristics, in-hospital and late (median follow-up: 13 months [interquartile range: 3 to 41 months]) outcomes analyzed according to the need of periprocedural PPI. All THVs except CoreValve, Cribier-Edwards, Sapien, and Sapien XT were considered to be new-generation THVs.RESULTS: A total of 1,987 patients without prior PPI undergoing ViV-TAVR from 2007 to 2020 were included. Of these, 128 patients (6.4%) had PPI after TAVR, with a significant decrease in the incidence of PPI with the use of new-generation THVs (4.7% vs. 7.4%; p = 0.017), mainly related to a reduced PPI rate with the Evolut R/Pro versus CoreValve (3.7% vs. 9.0%; p = 0.002). There were no significant differences in PPI rates between newer-generation balloon- and self-expanding THVs (6.1% vs. 3.9%; p = 0.18). In the multivariable analysis, older age (odds ratio [OR]: 1.05 for each increase of 1 year; 95% confidence interval [CI]: 1.02 to 1.07; p = 0.001), larger THV size (OR: 1.10; 95% CI: 1.01 to 1.20; p = 0.02), and previous right bundle branch block (OR: 2.04; 95% CI: 1.00 to 4.17; p = 0.05) were associated with an increased risk of PPI. There were no differences in 30-day mortality between the PPI (4.7%) and no-PPI (2.7%) groups (p = 0.19), but PPI patients exhibited a trend toward higher mortality risk at follow-up (hazard ratio: 1.39; 95% CI: 1.02 to 1.91; p = 0.04; p = 0.08 after adjusting for age differences between groups).CONCLUSIONS: In a contemporary large series of ViV-TAVR patients, the rate of periprocedural PPI was relatively low, and its incidence decreased with the use of new-generation THV systems. PPI following ViV-TAVR was associated with a trend toward increased mortality at follow-up.

KW - Aged

KW - Aged, 80 and over

KW - Female

KW - Humans

KW - Male

KW - Pacemaker, Artificial

KW - Prosthesis Implantation

KW - Registries

KW - Transcatheter Aortic Valve Replacement/methods

U2 - 10.1016/j.jacc.2021.03.228

DO - 10.1016/j.jacc.2021.03.228

M3 - SCORING: Journal article

C2 - 33958122

VL - 77

SP - 2263

EP - 2273

JO - J AM COLL CARDIOL

JF - J AM COLL CARDIOL

SN - 0735-1097

IS - 18

ER -